利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.008 秒)

    Hyaluronidase, isolation and pharmaceutical use thereof, and pharmaceutical and veterinary formulations containing it
    1.
    发明公开
    Hyaluronidase, isolation and pharmaceutical use thereof, and pharmaceutical and veterinary formulations containing it 失效
    HYALURONIDASE，隔离和药物使用，以及含有它的药物和兽医配方

    公开(公告)号：EP0193330A3

    公开(公告)日：1988-07-20

    申请号：EP86301092

    申请日：1986-02-17

    申请人： Biopharm (UK) Ltd.

    发明人： Sawyer, Roy Thomas ,  Edwards, Jeffrey

    IPC分类号： C12N09/26 ,  A61K37/54 ,  C12Q01/34

    CPC分类号： C12N9/2408 ,  A61K38/00 ,  Y10S514/912 ,  Y10S514/913

    摘要： The hyaluronidase, which is a hyaluronic acid-specific endo-B-glucuronidase, having a molecular weight of about 28,500 in non-reduced form, is derived from buffalo leeches (that is, leeches of the sub-family Hirudinariinae, such as the species Hirudinaria manillensis or Poecilobdella granulosa) The hyaluronidase, which cleaves hyaluronic acid, but not chondroitin, chondroitin -4- sulphate, chondroitin -6- sulphate or heparin, is considerably more stable at high temperatures and extremes of pH than known leech hyaluronidase. It has a wide range of uses where breakdown of hyaluronic acid is required; of particular interest is in pharmaceutical or veterinary formulations, either as an active agent or a spreading or percutaneous factor. The hyaluronidase is useful for stimulating flow of physiological fluids in the eye (for example, in the treatment of glaucoma).

    Improved method of determining antibiotics in biological liquids
    3.
    发明公开
    Improved method of determining antibiotics in biological liquids 失效
    确定生物液体中抗生素的改进方法

    公开(公告)号：EP0134078A3

    公开(公告)日：1986-03-12

    申请号：EP84303966

    申请日：1984-06-12

    申请人： WHITTAKER BIOPRODUCTS, INC.

    发明人： Klein, Hilton J.

    IPC分类号： C12Q01/34 ,  G01N33/04

    CPC分类号： G01N33/9446 ,  C12Q1/34 ,  G01N33/04 ,  G01N2333/986 ,  G01N2415/00

    摘要： The presence of beta lactum ring-containing cephalosporins and penicillin is determined in biological liquids such as milk by contacting the test liquid with a beta lactum ring-containing chromogenic compound and penicillinase and measuring after a predetermined time period the colour developed in the test liquid in comparison with a colour standard. Preferably, the colour standard is provided by contacting the same ingredients and concentrations for the same time period, exept that the liquid is free of beta lactum ring-containing cephalosporin and penicillin. The colourimetric test can be carried out within a few minutes (e.g. 3-15) utilizing a chromegenic compound such as nitrocefin, preferably on a solid phase substrate. The penicillinase attacks both the beta lactum ring of the chromogenic compound and any beta lactum ring-containing cephalosporin and/or penicillin present in the test liquid. The generation of colour due to breakage of the chromogenic compound's beta lactum ring is correspondingly reduced as the concentration of the beta lactum ring-containing antibiotic increases in the test liquid. Therefore, the method permits measurement of the concentration of such antibiotic in the test liquid. The method is simple, inexpensive, rapid and effective and can be run on equipment which is readily available in most laboratories.

    Process for determining inhibitor-enzyme complexes and composition for use therein
    4.
    发明公开
    Process for determining inhibitor-enzyme complexes and composition for use therein 失效
    用于确定抑制剂 - 酶复合物的方法及其用途的组合物

    公开(公告)号：EP0048989A3

    公开(公告)日：1982-05-12

    申请号：EP81107730

    申请日：1981-09-29

    申请人： BEHRINGWERKE AKTIENGESELLSCHAFT

    发明人： Harpel, Peter Cahners, Dr.

    IPC分类号： C12Q01/38 ,  G01N33/86 ,  C12Q01/34

    CPC分类号： G01N33/535 ,  C12Q1/37 ,  C12Q1/56 ,  G01N33/573 ,  G01N33/86 ,  G01N2333/81 ,  G01N2333/811

    摘要： This invention relates to methods for detecting, identifying and quantifying enzymes, for example, human proteolytic enzymes. The method broadly comprises forming an immobilized or insoluble complex comprising enzyme, enzyme inhibitor and enzyme inhibitor-antibody reactive site and then detecting and identifying, preferably quantitatively, one or more enzymes bound to the complex. In a preferrend embodiment, a matrix, e.g. solid or semisolid surface or permeable matrix, has affixed thereto enzyme inhibitor-antibody or an immunologically active (inhibitor binding) fragment of such an antibody. This insoluble enzyme inhibitor interacting matrix is then contacted with biological fluid, e.g. body fluid, to bind one or more predetermined enzyme inhibitor-enzyme complexes, if present in the biological fluid. The bound enzyme is then detected, identified and preferably quantified.